Speaker Profile
M.D., Ph.D., FCAP, Chief Medical Director, Palmetto GBA
Biography
Dr. Bien-Willner is the Medical Director of the MolDX program at Palmetto GBA, a Medicare Administrative Contractor (MAC). He is a leader in the Precision Medicine space and practices as a Board-certified Anatomic Pathologist and Molecular Genetic Pathologist. Throughout his career, he has been active in research, development, and advancement of molecular diagnostic services, specifically next generation sequencing. He has worked closely with clinicians to develop clear clinical diagnostic and treatment pathways directing Precision Medicine programs for community cancer centers. Dr. Bien-Willner received his MD and PhD degrees from Baylor College of Medicine, with a PhD in Human Molecular Genetics. He completed his residency, fellowship, and attained a faculty appointment at Washington University in St. Louis prior to leadership roles in laboratory and biotech companies before joining Palmetto GBA.
Session Abstract – PMWC 2025 Silicon Valley
Track Chair: Razelle Kurzrock, Medical College of Wisconsin
- PMWC 2025 Award Ceremony:
Luminary Honoree: Hedvig Hricak, Memorial Sloan Kettering
Pioneer Honoree: Michael E. Phelps, UCLA - Keynote: Precision Imaging for Precision Medicine
- Hedvig Hricak, Memorial Sloan Kettering
- Keynote: PET Imaging and Theranostics: Revolutionizing Cancer Detection and Treatment
- Michael E. Phelps, UCLA
- Radiopharmaceuticals for Cancer Therapy (PANEL)
Chair: Wiliam Oh, Yale Caner Center
- Naga Vara Kishore Pillarsetty, Memorial Sloan Kettering
- Jones Nauseef, Convergent Therapeutics
- Thomas Hope, UCSF
- Advancements in Digital Imaging: Enhancing Accuracy in Cancer Diagnostics
Chair: Razelle Kurzrock, Medical College of Wisconsin
- Hedvig Hricak, Memorial Sloan Kettering
- Eliot Siegel, VA Maryland Healthcare System
- Sharmila Majumdar, UCSF
- Wafik El-Deiry, Brown University - Digitalizing Oncology Care: Challenges and Opportunities (PANEL)
Chair: Christian Wolfrum, Siemens Healthineers
- Ashley Smith, Varian
- Marshall Pitz, Manitoba Cancer Care
- Measuring Tumor Aggressiveness: How Nanotechnology is Shaping the Future of Cancer Diagnostics
- Marija Plodinec, ARTIDIS
- Alastair Thompson, Baylor College of Medicine
- Stacey Tinianov, Advocates for Collaborative Education
- Overcoming Health System Barriers and Redefining Oncology Endpoints: The Role of MRD
- Krupa Paranjpe, Sanofi - Unlocking MRD Testing and Beyond: Combining Ultra-High Sensitivity WGS with Low Cost
- Gilad Almogy, Ultima Genomics - Ultra-Rapid NGS Testing: Why Time Matters
- Luca Quagliata, ThermoFisher
- Ibiayi Dagogo-Jack, Massachusetts General Hospital
- PMWC Showcase
- Tuvik Beker, Pangea Biomed
- Navigating Regulatory Hurdles and Reimbursement Pathways for Oncology Innovations
Chair: Sheila Walcoff, Goldbug Strategies
- Wui-Jin Koh, NCCN - Gabriel A. Bien-Willner, Palmetto GBA
- Erin Satterwhite, Optum Specialty Pharmacy
